Adjuvant chemotherapy for rectal cancer – Authors' reply
Gray, Richard and McConkey, Christopher C. (2008) Adjuvant chemotherapy for rectal cancer – Authors' reply. Lancet, Vol.371 (No.9623). p. 1503. ISSN 0140-6736Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/S0140-6736(08)60651-0
We agree with Krzysztof and Magdalena Bujko that a meta-analysis of individual patients' data is needed to resolve whether adjuvant chemotherapy produces worthwhile benefits in patients with rectal cancer who receive preoperative or postoperative radiotherapy.
The QUASAR study does, however, provide no reason to believe that chemotherapy is any more or less effective among patients who also receive radiotherapy.
|Item Type:||Journal Item|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Rectum -- Cancer, Cancer -- Adjuvant treatment -- Analysis, Chemotherapy -- Analysis|
|Journal or Publication Title:||Lancet|
|Publisher:||The Lancet Publishing Group|
|Official Date:||3 May 2008|
|Page Range:||p. 1503|
|Access rights to Published version:||Restricted or Subscription Access|
|Version or Related Resource:||Reply to Bujko, K. and Bujko, M. (2008). Adjuvant chemotherapy for rectal cancer. The Lancet, 371(9623), pp. 1502-1503.|
Actions (login required)